Yosuke Inoue

Dr. Yosuke Inoue

orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KIKentaro Inamura
Kentaro Inamura
YTYutaka Takazawa
Yutaka Takazawa
YIYosuke Inoue
Yosuke Inoue
YYYusuke Yokouchi
Yusuke Yokouchi
MKMaki Kobayashi
Maki Kobayashi
YIYuichi Ishikawa
Yuichi Ishikawa
B7-H3 (CD276), a member of the family of immune modulators, orchestrates antitumor immunity. To date, only small-sized studies have examined the association of B7-H3 expression with survival in pancreatic cancer, yielding inconclusive results. We evaluated tumor B7-H3 expression in 150 consecutive patients with pancreatic ductal adenocarcinoma using immunohistochemistry. B7-H3 expression was positive (≥10% tumor cells) in 99 of 150 (66%) cases of pancreatic cancer. We classified the tumors into four groups depending on B7-H3 expression (negative, low, intermediate, and high) and found that higher B7-H3 expression was independently associated with lower disease-free survival (DFS; for high vs. negative B7-H3 expression: multivariable hazard ratio (HR) = 3.12; 95% confidence interval (CI) = 1.48–6.15; Ptrend = 0.0026). Furthermore, the association of B7-H3 expression with survival differed according to the pathological stage (p-stage) (Pinteraction = 0.048, between p-stages I–II and III–IV). The association of B7-H3 positivity with lower DFS was stronger in tumors with p-stage I–II (multivariable HR = 3.10, 95% CI = 1.75–5.69; P < 0.0001) than in those with p-stage III–IV (multivariable HR = 1.20, 95% CI = 0.67–2.28; P = 0.55). We demonstrated that tumor high B7-H3 expression is independently associated with poor survival in patients with pancreatic cancer and that this association is stronger in tumors with p-stage I–II than in those with p-stage III–IV. B7-H3 expression may be a useful prognostic biomarker for identifying aggressive early-stage pancreatic cancer.

27 September 2021 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
AOAtsushi Oba
Atsushi Oba
MCMarco Del Chiaro
Marco Del Chiaro
Sohei SatoiSohei Satoi
Sohei Satoi
SKSun‐Whe Kim
Sun‐Whe Kim
HTHidenori Takahashi
Hidenori Takahashi
IEItaru Endo
Itaru Endo

16 March 2022 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
YUYuta Ushida
Yuta Ushida
YIYosuke Inoue
Yosuke Inoue
AOAtsushi Oba
Atsushi Oba
TMTakafumi Mie
Takafumi Mie
HIHiromichi Ito
Hiromichi Ito
YTYu Takahashi
Yu Takahashi

15 October 2020 in Journal of Hepato-Biliary-Pancreatic Sciences
Verified
Journal Article
Closed access
PDF file
YIYosuke Inoue
Yosuke Inoue
ASAkio Saiura
Akio Saiura
AOAtsushi Oba
Atsushi Oba
YOYoshihiro Ono
Yoshihiro Ono
YMYoshihiro Mise
Yoshihiro Mise
YTYu Takahashi
Yu Takahashi

24 October 2018 in BMC Surgery
Verified
Journal Article
Open access
PDF file
SKShoji Kawakatsu
Shoji Kawakatsu
YIYosuke Inoue
Yosuke Inoue
YMYoshihiro Mise
Yoshihiro Mise
TITakeaki Ishizawa
Takeaki Ishizawa
Hiromichi ItoHiromichi Ito
Hiromichi Ito
ASAkio Saiura
Akio Saiura
Postoperative pancreatic fistula (PF) is the main cause of operative mortality in patients who undergo pancreatoduodenectomy. Various pancreatoenteric anastomosis techniques have been reported to minimize the postoperative PF rate. However, the optimal method remains unknown. This study was performed to clarify the impact of pancreatojejunostomy on clinically relevant PF (CR-PF) between Blumgart anastomosis and Kakita anastomosis in patients with a soft pancreas. In total, 620 consecutive patients underwent pancreatoduodenectomy at our institute from January 2010 to December 2016, and 282 patients with a soft pancreas were analyzed (Blumgart anastomosis, n = 110; Kakita anastomosis, n = 176). Short-term outcomes were assessed, and univariate and multivariate analyses of several clinicopathological variables were performed to analyze factors affecting the incidence of CR-PF. The CR-PF rate was 42.7% (122/286). The CR-PF rate was not significantly different between the Blumgart and Kakita groups (42.7% and 42.6%, respectively; p = 0.985). The morbidity rate (Clavien–Dindo grade ≥ IIIa) was 24.5% (70/286), and the operation-related mortality rate was 0.7% (2/286). In the multivariate analysis, male sex (p = 0.0245) and a body mass index of ≥22 kg/m2 (p < 0.0001) were statistically significant risk factors for CR-PF. The CR-PF rate was not significantly different between patients treated with Kakita versus Blumgart anastomosis.

1 January 2021 in Pancreatology
Verified
Journal Article
Closed access
YUYuta Ushida
Yuta Ushida
YIYosuke Inoue
Yosuke Inoue
HIHiromichi Ito
Hiromichi Ito
AOAtsushi Oba
Atsushi Oba
YMYoshihiro Mise
Yoshihiro Mise
YTYu Takahashi
Yu Takahashi